Pharmacological management of renal fibrotic disease

Expert Opinion on Pharmacotherapy

Volumn 7, Issue 4, 2006, Pages 377-386

  Gaedeke, Jens ^a   Neumayer, Hans H ^a   Peters, Harm ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Aldosterone; Angiotensin II; Chronic kidney disease; Kidney fibrosis; TGF

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; ALISKIREN; AMLODIPINE; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; ATORVASTATIN; BENAZEPRIL; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; EPLERENONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRBESARTAN; LOSARTAN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAMIPRIL; RECEPTOR BLOCKING AGENT; SB 525334; SPIRONOLACTONE; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; VERAPAMIL;

ALBUMINURIA; ANEMIA; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG TARGETING; GLOMERULUS FILTRATION RATE; HEART MUSCLE FIBROSIS; HUMAN; HYPERKALEMIA; HYPERTENSION; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY FIBROSIS; KIDNEY FUNCTION; MONOTHERAPY; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; CALCIUM CHANNEL BLOCKERS; DISEASE PROGRESSION; DRUG EVALUATION, PRECLINICAL; DRUG THERAPY, COMBINATION; FIBROSIS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY; KIDNEY DISEASES; PRACTICE GUIDELINES; PROTEIN KINASE INHIBITORS; RANDOMIZED CONTROLLED TRIALS; RENIN-ANGIOTENSIN SYSTEM; TRANSFORMING GROWTH FACTOR BETA;

EID: 33644905287     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.7.4.377     Document Type: Review

References (92)

1. GAEDEKE J, PETERS H, NOBLE NA BORDER WA: Angiotensin II, TGF-beta and renal fibrosis. Contrib. Nephrol. (2001) 135-153-160.
2. TAAL MW, ZANDI-NEJAD K, WEENING B et al: Proinflammtory gene expression and macrophage recruitment in the rat remnant. Kidney Int. (2000) 58(4):1664-1676.
3. TAAL MW, CHERTOW GM, REENKE HG et al: Mechanisms underlying renoprotection during renin-angiotensin system blockade. Am. J. Physiol. Renal Physiol. (2001) 280(2):F343-F355.
4. BOHLE A, MACKENSEN-HAEN S, VON GISE H: Significance of tubulointerstitial changes in the renal cortex for the excretory Function and concentration ability of the kidney: a morphometric contribution. Am. J. Nephrol. (1987) 7(6):421-433.
5. PERICO N, PLATA R, ANABAYA A et al: Strategies for national health care systems in emerging countries: The case of screening and prevention of renal disease progression in Bolivia. Kidney Int. Suppl. (2005) 97:S87-S94.
6. CUSUMANO AM, DI GIOIA C, HERMIDA O LAVORATO C: The latin american dialysis and renal transplantation registry annual report 2002. Kidney Int. Suppl. (2005) 97:S46-S52.
7. BORDER WA NOBLE NA: Interactions of transforming growth factor-beta and angiotensin II in renal fibrosis. Hypertension (1998) 31(1 Pt 2):181-188.
8. KAGAMI S, BORDER VA, MILLER DE, NOBLE NA. Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells. J. Clin. Invest. (1994) 93(6):2431-2437.
9. WOLF G, MUELLER I, STAHL RA, ZIYADEH FN: Angiotensin II-induced hypertrophy of cultured routine proximal tubular cells is mediated by endogenous transforming growth factor-beta. J. Clin. Invest. (1993) 92(3):1366-1372.
10. KOBORI H, OZAWA Y, SUZAKI Y. NISHIYAMA A: Enhanced intrarenal angiotensinogen contributes to early renal injury in spontaneously hypertensive rats. J. Am. Soc. Nephrol. (2005) 16(7):2073-2080.
11. GRACIANO ML, CAVAGLIERE RDC, DELLE H et al: Intrarenal renin-angiotensin system is upregulated in experimental model of progressive renal disease induced by chronic inhibition of nitric oxide synthesis. J. Am. Soc. Nephrol. (2004) 15(7):1805-1815.
12. BADER M, PETERS J, BALTATU O, MULLER DN, LUFT FC, GANTEN D: Tissue renin-angiotensin systems: new insights from experimental animal models in hypertension research. J. Mol. Med. (2001) 79(2-3):76-102.
13. GAEDEKE J, BOEHLER T, BUDDE K, NEUMAYER H, PETERS H: Glomerular activin A overexpression is linked to fibrosis in and-Thy1 glomerulonephritis. Nephrol. Dial. Transplant.(2005) 20(2):319-328.
14. HUANG Y, HARAGUCHI M, LAWRENCE DA, BORDER WA, YU L, NOBLE NA: A mutant, noninhibitory plasminogen activator inhibitor Type 1 decreases matrix accumulation in experimental glomerulonephritis. J. Clin. Invest. (2003) 112(3):379-388.
15. NICHOLAS SB, AGUINIGA E, REN Y et al.: Plasminogen activator inhibitor-1 deficiency retards diabetic nephropathy. Kidney Int. (2005) 67(4):1297-1307.
16. ODA T, JUNG YO, KIM HS et al.: PAI-1 deficiency attenuates the fibrogenic response to ureteral obstruction. Kidney Int. (2001) 60(2):587-596.
17. YAMAMOTO T, NOBLE NA, COHEN AH et al.: Expression of transforming growth factor-beta isoforms in human glomerular diseases. Kidney Int. (1996) 49(2):461-469.
18. SHARMA K, ELTAYEB BO, MCGOWAN TA et al.: Captopril-induced reduction of serum levels of transforming growth factor-beta1 correlates with long-term renoprotection in insulin-dependent diabetic patients. Am. J. Kidney Dis. (1999) 34(5):818-823.
19. GREENE EL, KREN S, HOSTETTER TH: Role of aldosterone in the remnant kidney model in the rat. J. Clin. Invest. (1996) 98(4):1063-1068.
20. JUKNEVICIUS I, SEGAL Y, KREN S, LEE R, HOSTETTER TH: Effect of a1dosterone on renal transforming growth factor-beta. Am. J. Physiol. Renal Physiol. (2004) 286(6):F1059-F1062.
21. FUJISAWA G, OKADA K, MUTO S et al.: Spironolactone prevents early renal injury in streptozotocin-induced diabetic rats. Kidney Int. (2004) 66(4):1493-1502.
22. ENDEMANN DH, TOUYZ RM, IGLARZ M, SAVOIA C, SCHIFFRIN EL: Eplerenone prevents salt-induced vascular remodeling and cardiac fibrosis in stroke-prone spontaneously hypertensive rats. Hypertension (2004) 43(6):1252-1257.
23. ROCHA R, CHANDER PN, KHANNA K, ZUCKERMAN A, STIER CTJ: Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension (1998) 31 (1 Pt 2):451-458.
24. ROCHA R, CHANDER PN, ZUCKERMAN A, STIER CTJ: Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats. Hypertension (1999) 33 (1 Pt 2):232-237.
25. STRUTHERS AD: The clinical implications of aldosterone escape in congestive heart failure. Eur. J. Heart Fail. (2004) 6(5):539-545.
26. LAKKIS J, LU WX, WEIR MR: Raas escape: a real clinical entity that may be important in the progression of cardiovascular and renal disease. Curr. Hypertens. Rep. (2003) 5(5):408-417.
27. SCHJOEDT KJ, ANDERSEN S, ROSSING P, TARNOW L, PARVING H: Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate. Diabetalogia (2004) 47(11):1936-1939.
28. YOUNG M, FUNDER JW: EPLERENONE, but not steroid withdrawal, reverses cardiac fibrosis in deoxycorticosterone/salt-treatcd rats. Endocrinology (2004) 145(7):3153-3157.
29. FUNDER JW: RALES EPHESUS AND REDOX. J. Steroid Biochem. Mol. Biol. (2005) 93(2-5):121-125.
30. PITT B, ZANNAD F, REMME WJ et al.: The effect spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N. Engl. J. Med. (1999) 341(10):709-717.
31. PITT B, REICHEK N, WILLENBROCK R et al.: Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation (2003) 108(15):1831-1838.
32. ROMERO F, RODRIGUEZ-ITURBE B, PARRA G, GONZALEZ L, HERRERA-ACOSTA J, TAPIA E: Mycophenolate mofetil prevents the progressive renal failure induced by 5/6 renal ablation in rats. Kidney Int. (1999) 55(3):945-955.
33. BADID C, VINCENT M, MCGREGOR B et al.: Mycophenolate mofetil reduces myofibroblast infiltration and collagen III deposition in rat remnant kidney Int. (2000) 58(1):51-61.
34. KRAMER S, LOOF T, MARTINI S et al.: Mycophenolate mofetil slows progression in anti-thy1-induced chronic renal fibrosis but is not additive to a high dose of enalapril. Am J. Physiol. Renal Physiol. (2005) 289(2):F359-F368.
35. MAES BD, OYEN R, CLAES K et al.: Mycophenolate mofetil in IgA nephropathy: results of a 3-year prospective placebo-controlled randomized study, Kidney Int. (2004) 65(5):1842-1849.
36. FRISCH G, LIN J, ROSENSTOCK J et aL.: Mycophenolate mofetil (MMF) versus placebo in patients with moderately advanced IgA nephropathy: a double-blind randomized controlled trial. Nephrol. Dial. Transplant. (2005) 20(10):2139-2145.
37. LEWIS EJ, HUNSICKER LG, BAIN RP ROHDE RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N. Engl. J. Med. (1993) 329(20):1456-1462.
38. GISEN GROUP: Randomised placebo-controlled trial of effect of ran-tipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet (1997) 349(9096):1857-1863.
39. MASCHIO G, ALBERTI D, JANIN G et al.: Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N. Engl J. Med. (1996) 334(15):939-945.
40. BRENNER BM, COOPER ME, De Zeeuw D et aL.: Effects of losartan on renal and cardiovascular outcomes in patients with Type 2 diabetes and nephropathy. N. Engl. J. Med. (2001) 345(12):861-869.
41. LEWIS EJ, HUNSICKER LG, CLARKE WR et al.: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to Type 2 diabetes. N. Engl. J. Med. (2001) 345(12):851-860.
42. PARVING HH, LEHNERT H, BROCHNER-MORTENSEN J, GOMIS R, ANDERSEN S, ARNER P: The effect of irbesartan on the development of diabetic nephropathy in patients with Type 2 diabetes. N. Engl. J. Med. (2001) 345(12):870-878.
43. PETERS H, BORDER WA, NOBLE NA: Targeting TGF-beta overexpression in renal disease: maximizing the antifibrotic action of angiotensin II blockade. Kidney Int. (1998) 54(5):1570-1580.
44. CAMPBELL R, SANGALLI F, PERTICUCCI E et al.: Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies. Kidney Int. (2003) 63(3):1094-1103.
45. NAKAO N, YOSHIMURA A, MORITA H, TAKADA M, KAYANO T, IDEURA T: Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randormised controlled trial. Lancet (2003) 361(9352):117-124.
46. JACOBSEN P, ANDERSEN S, ROSSING K, JENSEN BR, PARVING H: Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy. Kidney Int. (2003) 63(5):1874-1880.
47. WOLF G, RITZ E: Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications. Kidney Int. (2005) 67(3):799-812.
48. RUGGENENTI P, MISE N, PISONI R et al.: Diverse effects of increasing lisinopril doses on lipid abnormalities in chronic nephropathies. Circulation (2003) 107(4):586-592.
49. ROSSING K, SCHJOEDT KJ, JENSEN BR, BOOMSMA F, PARVING H: Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with Type 2 diabetes and microalbuminuria. Kidney Int. (2005) 68(3):1190-1198.
50. JAFAR TH, STARK PC, SCHMID CH et al.: Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann. Intern. Med. (2003) 139(4):244-252.
51. FRANKLIN SS, JACOBS MJ, WONG ND, L'ITALIEN GJ, LAPUERTA P: Predominance of isolated systolic hypertension among middle-aged and elderly US hypertensives: analysis based on National Health and Nutrition Examination Survey (NHANES) 111. Hypertension (2001) 37(3):869-874.
52. PRIMATESTA P, BROOKES M POULTER NR: Improved hypertension management and control: results from the health survey for England 1998. Hypertension (2001) 38(4):827-832.
53. RUGGENENTI P, PERNA A. MOSCONI L, PISONI R, REMUZZI G: Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. Gruppo Italiano di Studi Epidermiologici in Nefrologia (GISEN). Kidney Int. (1998) 53(5):1209-1216.
54. RUGGENENTI P, PERNA A, RENUZZI G: Retarding progression of chronic renal disease: the neglected issue of residual proteinuria. Kidney Int. (2003) 63(6):2254-2261.
55. DONADELLI R, ZANCHI C, MORIGI M et aL.: Protein overload induces fractalkine upregulation in proximal tubular cells through nuclear factor kappaB- and p38 mitogen-activated protein kinase-dependent pathways. J. Am. Soc. Nephrol. (2003) 14(10):2436-2446.
56. LAVERMAN GD, NAVIS G, HENNING RH, DE JONG PE, DE ZEEUW D: Dual renin-angiotensin system blockade at optimal doses for proteinuria. Kidney Int. (2002) 62(3):1020-1025.
57. WRIGHT JTJ, BAKRIS G, GREENE T et aL.: Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from die AASK trial. JAMA (2002) 288(19):2421-2431.
58. RUGGENENTI P, PERNA A, BENINI R, REMUZZI G: Effects of dihydropyridine calcium channel blockers, angiotensin-converting enzyme inhibition, and blood pressure control on chronic, nondiabetic nephropathies. Gruppo Italiano di Studi Epidermiologici in Nefrologia (GISEN). J. Am. Soc. Nephrol. (1998) 9(11):2096-2101.
59. SHAH S, PAPARELLO J, DANESH FR: Effects of statin therapy on die progression of chronic kidney disease. Adv. Chronic Kidney Dis, (2005) 12(2):187-195.
60. BIANCHI S, BIGAZZI R, CAIAZZA A, CAMPESE VM: A controlled, prospective study of die effects of atorvastatin on proteinuria and progression of kidney disease. Am. J. Kidney Dis. (2003) 41(3):565-570.
61. SATO A, HAYASHI K, NARUSE M, SARUTA T: Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension (2003) 41(1):64-68.
62. SATO A, HAYASHI K, SARUTA T: Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease. Am. J. Hypertens. (2005) 18(1):44-49.
63. JUURLINK DN, MAMDANI MM, LEE DS et al.: Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N. Engl. J. Med. (2004) 351(6):543-551.
64. HUSSAIN S, DREYFUS DE, MARCUS RJ, BIEDERMAN RWW, MCGILL RL: Is spironolactone safe for dialysis patients? Nephrol. Dial. Transplant. (2003) 18(11):2364-2368.
65. SAUDAN P, MACH F, PERNEGER T et aL.: Safety of low-dose spironolactone administration in chronic haemodialysis patients. Nephrol. Dial. Transplant. (2003) 18(11):2359-2363.
66. REMUZZI G, RUGGENENTI P, PERNA A et al.: Continuum of renoprorection with losartan at all stages of Type 2 diabetic nephropathy: a post hoc analysis of the RENAAL trial results. J. Am. Soc. Nephrol. (2004) 15(12):3117-3125.
67. HOU FF, ZHANG X, ZHANG GH et al.: Efficacy and safety of benazepril for advanced chronic renal insufficiency. N. Engl. J. Med. (2006) 354(2):131-140.
68. GRYGIELKO ET, MARTIN WM, TWEED C et aL.: Inhibition of gene markers of fibrosis with a novel inhibitor of transforming growth factor-beta Type I receptor kinase in paromycin-induced nephritis. J. Pharmacol. Exp. Ther. (2005) 313(3):943-951.
69. GRADMAN AH, SCHMIEDER RE, LINS RL, NUSSBERGER J, CHIANG Y, BEDIGIAN MP: Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation (2005) 111(8):1012-1018.
70. PILZ B, SHAGDARSUREN E, WELLNER M et aL.: Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats. Hypertension (2005) 46(3):569-576.
71. NGUYEN G, DELARUE F, BERROU J, RONDEAU E SRAER JD: Specific receptor binding of renin on human mesangial cells in culture increases plasminogen activator inhibitor-1 antigen. Kidney Int. (1996) 50(6):1897-1903.
72. PETERS J, EARRENKOPF R, CLAUSMEYER S et aL.: Functional significance of prorenin internalization in the rat heart. Circ. Res. (2002) 90(10):1135-1141.
73. HUANG Y, WONGAMORNTHAM S, KASTING J et al.: Renin increases mesangial cell transforming growth factor-beta1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms. Kidney Int. (2006) 69(1):105-113.
74. BOFFA J, LU Y, PLACIER S, STEFANSKI A, DUSSAULE J, CHATZIANTONIOU C: Regression of renal vascular and glomerular fibrosis: role of angiotensin II receptor antagonism and matrix metalloproteinases. J. Am. Soc. Nephrol. (2003) 14(5):1132-1144.
75. ADAMCZAK M, GROSS M, KRTIL J et al.: Reversal of glomerulosclerosis after high-dose enalapril treatment in subtotally nephrectomized rats. J. Am. Soc. Nephrol. (2003) 14(11):2833-2842.
76. Chatziantoniou C, Dussaule J: Insights into the mechanisms of renal fibrosis: is it possible to achieve regression? Am. J. Physiol. Renal Physiol. (2005) 289(2):F227-F234.
77. ADAMCZAK M, GROSS M, AMANN K, RITZ E: Reversal of glomerular lesions involves coordinated restructuring of glomerular microvasculature. J. Am. Soc. Nephrol. (2004) 15(12):3063-3072.
78. DIEZ J, QUEREJETA R, LOPEZ B, GONZALEZ A, LARMAN M, MARTINEZ UBAGO JL: Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffliess in hypertensive patients. Circulation (2002) 105(21):2512-2517.
79. CIULLA MM, PALIOTTI R, ESPOSITO A et al: Different effects of antihypertensive therapies based on losartan or atenolol on ultrasound and biochemical markers of myocardial fibrosis: results of a randomized trial. Circulation (2004) 110(5):552-557.
80. FIORETTO P, STEFFES MW, SUTHERLAND DE, Goetz FC Mauer M: Reversal of lesions of diabetic nephropathy after pancreas transplantation. N. Engl. J. Med. (1998) 339(2):69-75.
81. RUGGENENTI P, PERNA A, BENINI R et al.: In chronic nephropathies prolonged ACE inhibition can induce remission: dynamics of time-dependent changes in GFR. Investigators of the GISEN Group. Gruppo Italiano Studi Epidemiologici in Nefrologia. J. Am. Sec. Nephrol. (1999) 10(5):997-1006.
82. HRUSKA KA, GUO G, WOZNIAK M et al: Osteogenic protein-1 prevents renal fibrogenesis associated with ureteral obstruction. Am. J. Physiol. Renal Physiol. (2000) 279(1):FI30-FI43.
83. ZEISBERG M, HANAI J, SUGIMOTO H et aL.: BMP-7 counteracts TGF-beta1-induced epithehal-to-mesenchymal transition and reverses chronic renal injury. Nat. Med. (2003) 9(7):964-968.
84. ZEISBERG M, BOTTIGLIO C, KUMAR N et al.: Bone morphogenic protein-7 inhibits progression of chronic renal fibrosis associated with two genetic mouse models. Am. J. Physiol. Renal Physiol. (2003) 285(6):FI060-FI067.
85. ZEISBERG M, SHAH AA KALLURI R: Bone morphogenic protein-7 induces mesenchymal to epithelial transition in adult renal fibroblasts and facilitates regeneration of injured kidney. J. Biol. Chem. (2005) 280(9):8094-8100.
86. HEEG MHJ, KOZIOLEK MJ, VASKO R et aL.: The antifibrotic effects of relaxin in human renal fibroblasts are mediated in part by inhibition of the Smad2 pathway. Kidney Int. (2005) 68(1):96-109.
87. SAMUEL CS, UNEMORI EN, MOOKERJEE I et al.: Relaxin modulates cardiac fibroblast proliferation, differentiation, and collagen production and reverses cardiac fibrosis in vivo. Endocrinology (2004) 145(9):4125-4133.
88. LEKGABE ED, KIRIAZIS H, ZHAO C et aL.: Relaxin reverses cardiac and renal fibrosis in spontaneously hypertensive rats. Hypertension (2005) 46(2):412-418.
89. LIU Y. Hepatocyte growth factor in kidney fibrosis: therapeutic potential and mechanisms of action. Am. J. Physiol. Renal Physiol. (2004) 287(1):F7-Fl6.
90. DE NICOLA L, MINUTOLO R, GALLO C et aL.: Management of hypertension in chronic kidney disease: the Italian multicentric study. J. Nephrol. (2005) 18(4)-397-404.
91. PERALTA CA, HICKS LS, CHERTOW GM et aL.: Control of hypertension in adults with chronic kidney disease in the United States. Hypertension (2005) 45(6):1119-1124.
92. ANDROS V: Uncontrolled blood pressure in a treated, high-risk managed care population. Am. J. Manag. Care (2005) 11(7 Suppl.):S215-S219.